Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corp (NY: CVM )

2.070 -0.180 (-8.00%)
Official Closing Price Updated: 8:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 717,735
Open 2.220
Bid (Size) 2.060 (10)
Ask (Size) 2.110 (3)
Prev. Close 2.250
Today's Range 2.050 - 2.270
52wk Range 1.040 - 3.330
Shares Outstanding 47,260,097
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire

Performance

YTD
-16.19%
-16.19%
1 Month
+24.70%
+24.70%
3 Month
+48.92%
+48.92%
6 Month
-14.81%
-14.81%
1 Year
-31.46%
-31.46%

More News

Read More
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why CEL-SCI (CVM) Shares Are Down 20%
Via Benzinga
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
Via FinancialNewsMedia
Exposures Product Safety
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
From CEL-SCI Corporation
Via Business Wire
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
US Stocks Mixed; Bank of America Tops Q2 Views
Via Benzinga
TDOC Stock Alert: Teladoc Doubles Down on Microsoft AI Partnership
Via InvestorPlace
CMG Stock Alert: Chipotle Announces International Expansion Plan
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is CEL-SCI (CVM) Stock Down 23% Today?
Via InvestorPlace
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.